The Ophthalmology Department at the Queen Elizabeth Hospital (QEH) has introduced a cutting-edge diagnostic test poised to revolutionize the detection of numerous eye ailments, including diabetes, sickle cell disease, and retinal vein occlusion.
On Tuesday, February 20, the inaugural Fundus Fluorescein Angiography (FFA) was conducted at the QEH, marking a significant milestone in eye care diagnostics.
Spearheaded by Consultant Medical Retinal Specialist, Dr. Charles Pierce, the procedure promises to elevate diagnostic precision, furnishing vital insights into conditions impacting the posterior segment of the eye.
A deeper insight
Dr. Pierce elucidated the significance of the FFA, highlighting its capacity to furnish comprehensive diagnostic data.
By administering a dye injection into the arm and capturing a series of images of the retina, the procedure unveils intricate details of the ocular vasculature, enabling clinicians to discern anomalies and initiate timely interventions.
Visionary care
Emphasizing the pivotal role of early detection in preserving vision, Dr. Pierce underscored the test’s utility in combating diabetic eye disease.
With its capability to detect pathology at its nascent stage, the FFA empowers healthcare providers to intervene promptly, mitigating the risk of vision loss.
Proactive patient care
Addressing the burgeoning diabetic population, Dr. Pierce urged regular eye examinations, particularly among individuals with diabetes.
Stressing the asymptomatic nature of early-stage eye diseases, he emphasized the imperative of annual screenings to preemptively identify and manage ocular complications.
Expanding horizons in eye care
The inauguration of the FFA heralds a new era in eye care at the Lions Eye Care Centre, bolstering the hospital’s diagnostic armamentarium. With comprehensive coverage across various ophthalmic subspecialties, the QEH is poised to confront a spectrum of ocular pathologies, reaffirming its commitment to delivering exemplary patient care.
















